Issued: London UK - LSE Announcement
GSK announces that Sir Philip Hampton has been appointed Chairman of the Nominations Committee (the "Committee") with effect from today, replacing Sir Christopher Gent, who will continue to serve as a member of the Committee for the remainder of his tenure on the Board.
In addition, Ms Lynn Elsenhans has also been appointed a member of the Committee, effective today.
The membership of the Nominations Committee is now:
Committee Chairman | Sir Philip Hampton | Chairman Designate |
Members | Sir Christopher Gent | Chairman |
Professor Sir Roy Anderson | Scientific & Medical Expert | |
Lynn Elsenhans | Non Executive Director | |
Judy Lewent | Audit & Risk Committee Chairman | |
Sir Deryck Maughan | Senior Independent Director | |
Tom de Swaan | Remuneration Committee Chairman |
GSK - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors' in the company's Annual Report on Form 20-F for 2013.
distributed by |